Press Releases

Date	Title and Summary
Toggle SummaryOctober 23, 2019	Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock REDWOOD CITY, Calif. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of
Toggle SummaryOctober 22, 2019	Soleno Therapeutics Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common
Toggle SummaryOctober 2, 2019	Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has, for the second time,
Toggle SummarySeptember 24, 2019	Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome Data Published for First Time in Peer-Reviewed Journal REDWOOD CITY, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that
Toggle SummarySeptember 19, 2019	Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies REDWOOD CITY, Calif. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle SummaryAugust 7, 2019	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results REDWOOD CITY, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the second
Toggle SummaryJuly 25, 2019	Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the Company’s ongoing Phase III trial,
Toggle SummaryJune 12, 2019	Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors REDWOOD CITY, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the appointment of Birgitte Volck , M.D., Ph.D., a veteran
Toggle SummaryMay 13, 2019	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results REDWOOD CITY, Calif. , May 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three
Toggle SummaryApril 29, 2019	Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors REDWOOD CITY, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Gwen A.

Print Page RSS Feeds Email Alerts IR Contacts